Chang Li of FinCity.Tokyo explains why global fintech startups are choosing Tokyo, from government support and open corporations to agentic AI and local partnerships.
Mark Walker, editorial director of the FinTech Times, interviewed Chang Li about Tokyo's growth as a fintech hub.
Blockchain Capital leads a Series C backing PhotonPay's bid to make stablecoins routine infrastructure for corporate treasury and cross-border settlement.
Blockchain Capital leads a Series C backing PhotonPay's bid to make stablecoins routine infrastructure for corporate treasury and cross-border settlement.
Hub71-backed Vivan Therapeutics launches a UAE clinical study for its genomics-matched cancer decision tool, generating the Gulf's first reimbursement evidence.
Hub71-backed Vivan Therapeutics launches a UAE clinical study for its genomics-matched cancer decision tool, generating the Gulf's first reimbursement evidence.
Chang Li of FinCity.Tokyo explains why global fintech startups are choosing Tokyo, from government support and open corporations to agentic AI and local partnerships.
Mark Walker, editorial director of the FinTech Times, interviewed Chang Li about Tokyo's growth as a fintech hub.
Blockchain Capital leads a Series C backing PhotonPay's bid to make stablecoins routine infrastructure for corporate treasury and cross-border settlement.
Blockchain Capital leads a Series C backing PhotonPay's bid to make stablecoins routine infrastructure for corporate treasury and cross-border settlement.
ACM Research has delivered its first 310 × 310 mm horizontal electroplating production system to an Asian customer, marking a milestone in panel-level advanced packaging.
ESET's domain-specific cybersecurity AI model underpins its LiveCortex platform, cutting training costs 200-fold versus general-purpose models, the company says.
SGU and Dubai's Fairgreen International School have agreed an affiliation giving IB students guaranteed interview access and up to $80,000 in scholarship support.
Genmab's bispecific antibody petosemtamab plus pembrolizumab met dual primary endpoints in first-line PD-L1+ head and neck cancer, halving the risk of death.